2 results
Approved WMORecruiting
Dose escalationPrimary• To determine the RP2D of single-agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-VEGF therapy, and with an anti-EGFR therapy (if RASwt)Secondary• To characterize the safety and…
Approved WMOCompleted
To record and analyse the electrophysiological properties and differences of the human pituitary gland, i.e. the anterior lobe, posterior lobe and adenoma.